COMP <GO>
ARWR vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
Arrowhead Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: ARWR 5
— MRK 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $59.90 (-0.98%) • MKT CAP: $8.54B
roic
11.10%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARWR VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARWR | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 11.10% | 20.70% | -9.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.8x | 15.3x | +58.50 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 1.84% | 3.42% | -1.58 | MRK | /fcf-yield <GO> |
| Operating Margin | 11.90% | 34.30% | -22.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 28.10% | -28.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 1.30% | +178.70 | ARWR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 5.19 | +1.41 | ARWR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ARWR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.60% | +0.20 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.9 | 56.9 | -15.98 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.92 | +0.04 | ARWR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 18.4x | -0.40 | ARWR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.54B | $361.02B | -$352.48B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARWR REV | MRK REV | ARWR GROSS % | MRK GROSS % | ARWR FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $829.4M | $65.01B | 44.0% | 74.8% | $156.9M | $12.36B |
| FY 2024 | $3.6M | $64.17B | 44.0% | 76.3% | -$604.3M | $18.10B |
| FY 2023 | $240.7M | $60.12B | 44.0% | 44.0% | -$164.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARWR // BETA 0.96
MRK // BETA 0.92